Motif Bio Share Discussion Threads

[rk23] 05/4/2019 08:08

8.5p, by 8.30.....

[newtothisgame3] 05/4/2019 06:32

#MTFB The market was confident in the prospects of #Motif #Bio
Its stock rose – which doesn't always happen after a placing – by 13.5 per cent, or 0.88p, ...

[newtothisgame3] 05/4/2019 06:32

#MTFB The market was confident in the prospects of #Motif #Bio
Its stock rose – which doesn't always happen after a placing – by 13.5 per cent, or 0.88p, ...

[newtothisgame3] 04/4/2019 20:57

#MTFB #Motif #Bio up 15% premarket ahead of Inclaprim presentations
Apr. 4, 2019 9:21 AM ET

[newtothisgame3] 04/4/2019 20:57

#MTFB #Motif #Bio up 15% premarket ahead of Inclaprim presentations
Apr. 4, 2019 9:21 AM ET

[newtothisgame3] 04/4/2019 20:47

#MTFB average analyst price target is $3.5 per share. This means the stock has a potential increase of 83.25% from where the MTFB share price has been trading recently which is between $1.82 and $1.8999 with one of them, even setting their price target at $5. By Peggy Goldman - April 4, 2019

[newtothisgame3] 04/4/2019 20:47

#MTFB average analyst price target is $3.5 per share. This means the stock has a potential increase of 83.25% from where the MTFB share price has been trading recently which is between $1.82 and $1.8999 with one of them, even setting their price target at $5. By Peggy Goldman - April 4, 2019

[volsung] 04/4/2019 15:03

Added another third to my holdings here. Over 10p soon.

[newtothisgame3] 04/4/2019 11:31

#MTFB #STRONG #BUY

[newtothisgame3] 04/4/2019 11:31

#MTFB #STRONG #BUY

[newtothisgame3] 04/4/2019 10:48

#MTFB Participation in the ECCMID will certainly add legitimacy and clout for #iclaprim.

[newtothisgame3] 04/4/2019 10:48

#MTFB Participation in the ECCMID will certainly add legitimacy and clout for #iclaprim.

[lionheart69uk1] 04/4/2019 09:36

That presentation looks promising.

[ivyspivey] 04/4/2019 09:07

Replace link with capital H on hxxps

[ivyspivey] 04/4/2019 09:06

Oral Presentation No.4 is interesting one imo

hxxps://www.eccmidlive.org/#resources/pharmacokinetics-of-iclaprim-by-age-weight-race-and-renal-hepatic-function-in-patients-with-acute-bacterial-skin-and-skin-structure-infections-phase-iii-revive-trials-dae8b942-d512-4d56-98e6-b4888e5b7b42

Specifically mentions Iclaprim clearance being effected by Age but no hepatic/liver function effect.

But maybe about FDA wanting an adjusted dose level say to 40mg for elderly patients as they have a concern over DILI in this group of patients and MTFB being confident there are no issues.

If this is case can be sorted out with straightforward label adjustment if necessary

[lw425] 04/4/2019 09:02

The problem here is that depending on what the FDA say, the company may need a lot of money to resubmit the NDA and wait another very long time for approval.

[small crow] 04/4/2019 08:52

Interesting trading today - on the good side.

[andrewsr] 04/4/2019 08:48

IMO they're in a better position now than they were at 40p as they are now focusing on just one issue. If they get a clear path to satisfying the FDA requirements on 3 May that will be effectively a conditional approval IMO. GLA.

[small crow] 04/4/2019 08:44

Nick, then you have what we have.

[deanmatlazin] 04/4/2019 08:33

It is only the liver data that FDA required. It is straight forward..compiling data and present it to FDA. This is no brainer. Will go back up again to 40p again after meeting with FDA. Fingers crossed.

[newtothisgame3] 04/4/2019 08:31

#MTFB NO1 COMING #Motif #BioSciences, New York, United States no iclaprim dose adjustments are needed for obese or renally impaired patients. 💼💼💼💼8188;💼ԁ88;💼💼;💼

[newtothisgame3] 04/4/2019 08:30

#MTFB NO1 COMING #Motif #BioSciences, New York, United States no iclaprim dose adjustments are needed for obese or renally impaired patients. 💼💼💼💼8188;💼ԁ88;💼💼;💼

[nick rubens] 04/4/2019 08:30

small crow "Read the letter"

Where is it available to read then? All I am aware of, is the board have it.

[enewman36] 04/4/2019 08:14

Well today's RNS was enough to convince me that they are confident that they can push this through, otherwise why have 4 presentations, thus I have averaged down just now, if I can sell other stocks I will do so to average down further, this could be a huge opportunity for us all.